French National Cancer Institute Scientific Report / 2015-2016 Scientific Report / 2015-2016
Total Page:16
File Type:pdf, Size:1020Kb
OCTOBER 2016 For more information e-cancer.fr 2015-2016 / Institut National du Cancer 52, avenue André Morizet FRENCH NATIONAL 92100 Boulogne-Billancourt France REPORT SCIENTIFIC Tel. +33 (0) 1 41 10 50 00 CANCER INSTITUTE [email protected] SCIENTIFIC REPORT / 2015-2016 FRENCH NATIONAL CANCER INSTITUTE CANCER INSTITUTE FRENCH NATIONAL RAPCSANG16 FRENCH NATIONAL CANCER INSTITUTE FRENCH NATIONAL CANCER INSTITUTE SCIENTIFIC REPORT / 2015-2016 SCIENTIFIC REPORT / 2015-2016 The French National Cancer Institute is the health and science agency in charge of cancer control. Since 2003, the fight against cancer in France has been structured around national plans to mobilise all stakeholders on prevention, screening, care, research and support for patients and their friends and families. The 2003-2007 Cancer Control Plan set up the first comprehensive 52, avenue André Morizet strategy to fight cancer; the second Cancer Control Plan (2009-2013) introduced the notion of 92100 Boulogne-Billancourt personalised care. France The 2014-2019 Cancer Control Plan intends to give each and every person, all over France, the Tel. +33 (0) 1 41 10 50 00 same chances for recovery and implement innovation even faster for [email protected] Plan patient benefit. Cancer This plan includes 17 objectives, all gathered around four major 2014-2019 health priorities: l Cure more patients l Preserve continuity and quality of life l Invest in prevention and research l Optimise management and the organisations efficiency The Cancer Control Plan falls within the implementation of a national health strategy and the “France-Europe 2020” Strategic Agenda for research, technology transfer and innovation. All rights reserved. This work may not be translated or copied in whole or in part without the written permission of Institut National du Cancer. According to the Code of intellectual property, only copies strictly reserved for private use and not for a collective one, or brief excerpts justified by the scientific nature or information of the work into which they are incorporated, Published by the French National Cancer Institute are authorised. All rights reserved – Siren 185 512 777 Conception: INCa This document was published in October 2016. It is available at the following address: Realised by Institut National du Cancer (INCa) ISSN 2276-5751 Direction de la recherche ISBN : 978-2-37219-242-2 52, avenue André Morizet – 92100 Boulogne-Billancourt ISBN net : 978-2-37219-243-9 e-cancer.fr © 2016. Institut National du Cancer (INCa) DEPÔT LÉGAL OCTOBRE 2015 FRENCH NATIONAL CANCER INSTITUTE 3 2015-2016 SCIENTIFIC REPORT SCIENTIFIC REPORT 2015-2016 FRENCH NATIONAL CANCER INSTITUTE 4 2015-2016 SCIENTIFIC REPORT TABLE OF CONTENTS PREAMBLE 6 3. CLINICAL RESEARCH AND DEVELOPMENT OF EARLY‑PHASE TRIALS FOR INNOVATIVE DRUGS 56 Key figures 8 3.1. Clinical cancer research programmes 56 Clinical trials indicators 11 3.2. Early‑phase clinical trials for innovative drugs 59 Molecular genetics centres: activity indicators 12 3.3. Personalised medicine tools and programmes 62 International framework 14 3.4. Organisation of clinical research and strengthening of structures, infrastructures and tools 68 SUMMARY OF THE REPORT 17 4. RESEARCH IN HUMAN AND SOCIAL SCIENCES, Part 1. EPIDEMIOLOGY AND PUBLIC HEALTH 72 Summary of previous recommendations 4.1. The recurrent programme for Human and social of the members of the international Scientific Sciences (HSS), Epidemiology and Public Health (EPH) Advisory Board and corresponding achievements 19 Research 72 Part 2. 4.2. Population Health Intervention research 75 Report on 2015-2016 cancer research activity 29 4.3. Initiatives developed to support research on environmental risks 77 1. SUPPORT IN BIOLOGY AND BASIC SCIENCES 4.4. PhD Programme in HSS‑EPH 2016 in collaboration FOR CANCER RESEARCH 31 with academic partners 79 1.1. Research programmes 31 1.2. The genomic and the epigenomic programmes 40 5. INTERNATIONAL COMMITMENTS 81 5.1. Strategic vision, mission and values 81 2. TRANSLATIONAL AND INTEGRATED RESEARCH 45 5.2. INCa’s European commitments 82 2.1. Research programmes aiming to accelerate 5.3. INCa’s global commitments 84 cross‑disciplinarity and transfer of knowledge to clinical practice 45 6. BIBLIOMETRIC STUDY, EVALUATION AND REVIEW 2.2. The Translational and multisdisciplinary Research OF RESEARCH INVESTMENT 90 Training Programmes 50 6.1. Bibliometric study 90 2.3. Strengthening of organisation and infrastructures 6.2. Focus: Trends in the French funding stream dedicated to translational/integrated research of intervention research addressing all aspects in integrated cancer research sites (SIRICs) 54 of cancer control, a cross‑sectional analysis 2010‑2014 95 6.3. International evaluation 97 6.4. Review of research investments 98 FRENCH NATIONAL CANCER INSTITUTE 5 2015-2016 SCIENTIFIC REPORT Part 3. Conclusion 118 Focus on strategic topics for advancing cancer research 103 Appendices 119 1. CHALLENGES ASSOCIATED WITH THE ARRIVAL OF IMMUNOTHERAPIES 106 1. CLINICAL TRIALS REGISTRY 120 1.1. Biological and clinical databases: a unique tool to assess and monitor immune checkpoint inhibitors efficacy 106 2. CSO‑COMMON SCIENTIFIC OUTLINE 122 1.2. Resources and infrastructures integration to face the immunotherapy challenges 107 3. 2014‑2019 CANCER CONTROL PLAN ACTIONS PROGRESS RELATED TO CANCER RESEARCH 123 2. THE TRIPOD PROGRAMME: GENERATION, INTEGRATION AND SHARING OF BIOLOGICAL AND CLINICAL DATA WITHIN THE SCOPE OF PRECISION MEDICINE 109 2.1. Data collection and integration: development of decision‑making tools 109 2.2. Data sharing for coordinated targeted therapies assessment 110 3. STUDYING TO SET UP A SPECIFIC PROGRAMME SUPPORTING LATE‑PHASE CLINICAL TRIALS 111 3.1. Late clinical trials close to cancer care management to improve patients’ survival 111 3.2. Identifying the main challenges of current clinical practices 112 4. STRENGTHENING THE STRUCTURING OF CANCER PUBLIC HEALTH RESEARCH 113 4.1. Fostering the capabilities of human and social sciences, epidemiology and public health 113 4.2. Supporting the visibility of human and social sciences, epidemiology and public health research 113 5. NEW INTERNATIONAL COMMITMENTS 115 5.1. European initiative FLAG‑ERA on digital medicine for cancer 116 5.2. Joint Action on Rare Cancers 116 5.3. Global network on prostate cancer 117 FRENCH NATIONAL CANCER INSTITUTE 6 2015-2016 SCIENTIFIC REPORT PREAMBLE The 2015‑2016 scientific report, prepared by INCa in collaboration with Aviesan Cancer Institute (ITMO Cancer‑Aviesan), summarises the activities carried out this year in the field of research and innovation supported by the National cancer control plan (NCCP). We would like to take the opportunity to thank the Scientific Advisory Board’s (SAB) members for advising and guiding the Institute during its structuring process and providing relevant recommendations for its initiatives. The present report highlights the input of INCa and ITMO Cancer‑Aviesan during this 12‑month period to pursue the task of providing strong support in basic science research, translational research and training, clinical research, and research in the fields of human and social sciences, epidemiology and public health through the coordination of research programmes with its partners and the support of infrastructures and networks. The critical analysis of each programme is provided herein. This period’s focus has been on tobacco prevention, management of children with cancer and access to personalised medicine. Through all these different programmes, INCa has had an instrumental role on a European and international scale. The Cancer control plan intends to develop and roll out targeted therapies and personalised medicine and to strengthen the links between care and research, and transversely, places an emphasis on support and access to innovation for the treatment of malignant diseases. INCa coordinates personalised medicine programmes based on the patient’s tumour molecular profile, the PAOLA clinical trial including European centres based on BRCA status and the AcSé programme. The latter was described in Nature Reviews Clinical Oncology and the results of the two first AcSé programmes presented at ASCO 2016 meeting. Additionally, spin‑off results from INCa’s participation in the International Cancer Genome Consortium (ICGC) were achieved in 2016 with major results from two studies of the Breast Cancer Project, launched in 2008, published in Nature and Nature Communications showing how whole exome sequencing will further allow better tumour definition and disease classification. The role of coordination and support in cancer research of INCa and ITMO Cancer‑Aviesan cannot be achieved without providing strong parallel support whether at the funding or management level of structures and infrastructures. By way of example, the above achievements in personalised medicine and FRENCH NATIONAL CANCER INSTITUTE 7 2015-2016 SCIENTIFIC REPORT patient access to therapy could not be achieved without the molecular screening performed in the 28 molecular genetics centres throughout France, the collaborative clinical groups or the 16 early‑phase clinical trials centres (CLIP²) and the collaboration with its partners on a national and international level, in the academic or private sector. Multidisciplinary integrative cancer research is supported on a regional level by the Cancéropôles, Biological and clinical databases (BCBs) for specific tumours, and Integrated cancer research sites (SIRICs). In addition,